Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 81, 2021 - Issue 6
Submit an article Journal homepage
305
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

Kristian Buch-Larsena Department of Endocrinology, Diabetes and Bone-metabolic Research Unit, Rigshospitalet, Copenhagen, DenmarkCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8133-1554View further author information
ORCID Icon,
Niklas Rye Jørgensenb Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark;c Faculty of Health Sciences, University of Copenhagen, Copenhagen, DenmarkORCID Iconhttps://orcid.org/0000-0001-9624-5210View further author information
ORCID Icon,
Lars Thorbjørn Jensenc Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark;d Department of Clinical Physiology and Nuclear Medicine, Herlev Gentofte Hospital, Copenhagen, DenmarkView further author information
,
Michael Anderssone Department of Oncology, Rigshospitalet, DenmarkView further author information
&
Peter Schwarza Department of Endocrinology, Diabetes and Bone-metabolic Research Unit, Rigshospitalet, Copenhagen, Denmark;c Faculty of Health Sciences, University of Copenhagen, Copenhagen, DenmarkView further author information
Pages 425-431 | Received 12 Mar 2021, Accepted 09 May 2021, Published online: 13 Jun 2021

References

  • Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386.
  • Autier P, Boniol M, Gavin A, et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ. 2011;343:d4411.
  • Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–30.
  • Bradley R, Burrett J, Clarke M, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–1352.
  • Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300.
  • Coleman R, Gray R, Powles T, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–1361.
  • Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006;24(33):5305–5312.
  • Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–1309.
  • Zhao X, Hu X. Dosing of zoledronic acid with its anti-tumor effects in breast cancer. J. Bone Oncol. 2015;4(3):98–101.
  • Gunmalm V, Jørgensen NR, Abrahamsen B, et al. Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors. Eur Geriatr Med. 2017;8(5–6):408–412.
  • Hadji P, Aapro M, Costa L, et al. Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. Cancer Treat Rev. 2012;38(6):815–824.
  • Deeks ED. Denosumab: a review in postmenopausal osteoporosis. Drugs and Aging. 2018;35:163–173.
  • Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–443.
  • Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398–405.
  • Theodorou DJ, Theodorou SJ. Dual-energy X-ray absorptiometry in clinical practice: application and interpretation of scans beyond the numbers. Clin Imaging. 2002;26(1):43–49.
  • Bundred NJ. Aromatase inhibitors and bone health [Internet]. Curr Opin Obstet Gynecol. 2009;21(1):60–67.
  • Thuesen B, Husemoen L, Fenger M, et al. Determinants of vitamin D status in a general population of Danish adults. Bone. 2012;50(3):605–610.
  • Vojdeman FJ, Madsen CM, Frederiksen K, et al. Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark. Int J Cancer. 2019;145:338–346.
  • Nogues X, Servitja S, Peña MJ, et al. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas. 2010;66(3):291–297.
  • Jerzak KJ, Raphael J, Desautels DN, et al. Bone-targeted therapy in early breast cancer. Oncology. 2018;32:562–569.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.